Britannia Life Sciences Inc.
BLAB
CNSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | 88.83% | -62.37% | -- | -- |
| Total Depreciation and Amortization | -- | 1.80% | 4.02% | -- | -- |
| Total Amortization of Deferred Charges | -- | 28.41% | 50.00% | -- | -- |
| Total Other Non-Cash Items | -- | -83.32% | 34.34% | -- | -- |
| Change in Net Operating Assets | -- | 134.95% | 645.69% | -- | -- |
| Cash from Operations | -- | 649.39% | 594.74% | -95.99% | -44.10% |
| Capital Expenditure | -- | -373.68% | -11.76% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 3.14% | -8.97% | -- | -- |
| Cash from Investing | -- | -7.28% | -9.05% | 52.02% | 81.25% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | 0.67% | -11.23% | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -389.83% | 137.26% | 8.74% | -17.66% |
| Foreign Exchange rate Adjustments | -- | -103.30% | 254.26% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -94.54% | 140.61% | -45.26% | 50.61% |